
William Blair initiated coverage for Climb Bio (NASDAQ:CLYM), citing the potential of the company’s budoprutug, under development for autoimmune indications, including:
- Phase 1b/2a immune thrombocytopenia (ITP) trial FPI achieved, enrollment ongoing.
- Phase 1b systemic lupus erythematosus (SLE) trial FPI achieved, enrollment ongoing.
- Phase 2 primary membranous nephropathy (pMN) trial will initiate in the coming weeks.